Gena Volas Redd, MD
Hematology & Oncology · Marietta, GANPI 1104804798
Payments from drug & device makers
Across 257 payments — averaging $2886.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi US Services Inc.$400K
- Genentech, Inc.$105K
- Novartis$91K
- AstraZeneca$68K
- Pfizer$32K
- Novocure GmbH$25K
- plus $20K from 30 others
What the payments were for
- Consulting fees$19,06825%
- Speaking & faculty fees$44,33058%
- Travel & lodging$8,73411%
- Food & beverage$4,5036%
- Education$3450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi US Services Inc. | 29 | $400,329 |
| Genentech, Inc. | 19 | $104,683 |
| Novartis | 33 | $91,094 |
| AstraZeneca | 13 | $68,350 |
| Pfizer | 67 | $31,820 |
| Novocure GmbH | 4 | $25,469 |
| Lilly USA, LLC | 4 | $5,127 |
| Daiichi Sankyo Inc. | 12 | $4,798 |
| Seagen Inc. | 8 | $3,435 |
| Novocure Inc. | 8 | $3,138 |
| Stemline Therapeutics Inc. | 1 | $2,160 |
| E.r. Squibb & Sons, L.L.C. | 3 | $138 |
| Gilead | 6 | $136 |
| Array Biopharma Inc | 12 | $112 |
| Sanofi | 3 | $85 |
| Genentech USA, Inc. | 4 | $84 |
| Puma Biotechnology, Inc. | 3 | $67 |
| Exelixis Inc. | 2 | $67 |
| Coherus Oncology, Inc. | 3 | $62 |
| Mirati Therapeutics, Inc. | 3 | $59 |
| GSK | 2 | $56 |
| Merck | 2 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $44 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $42 |
| Regeneron Healthcare Solutions, Inc. | 2 | $37 |
| Astellas Pharma US Inc | 1 | $33 |
| Bristol Myers Squibb | 1 | $33 |
| Tesaro, Inc. | 1 | $29 |
| Tempus AI, Inc | 1 | $29 |
| Immunogen, Inc. | 1 | $28 |
| Johnson & Johnson | 1 | $28 |
| Beigene USA, Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $24 |
| Servier Pharmaceuticals LLC | 1 | $23 |
| AbbVie | 1 | $21 |
| Fortovia Therapeutics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$741,734 in reported general payments places this provider in the 85th percentile of 370 hematology & oncology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IbrancePalbociclib | 43 | $661,213 |
| RevlimidLenalidomide | 30 | $599,291 |
| ImbruvicaIbrutinib | 30 | $409,395 |
| TruqapCapivasertib | 18 | $377,645 |
| VerzenioAbemaciclib | 22 | $367,277 |
| PomalystPomalidomide | 11 | $257,369 |
| Lenalidomide | 15 | $234,963 |
| TasignaNilotinib Hcl | 13 | $191,132 |
| BrukinsaZanubrutinib | 12 | $145,984 |
| EliquisApixaban | 120 | $96,937 |
| XareltoRivaroxaban | 50 | $40,241 |
| CreonLipase/Protease/Amylase | 21 | $31,667 |
| Letrozole | 203 | $3,859 |
| Anastrozole | 233 | $3,681 |
| Fentanyl | 40 | $3,050 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $31,820 | $758,150163 claims |
| Bristol Myers SquibbRevlimid | $33 | $599,29130 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $42 | $409,39530 claims |
| AstraZenecaTruqap | $68,350 | $377,64518 claims |
| Lilly USA, LLCVerzenio | $5,127 | $367,27722 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $138 | $257,36911 claims |
| NovartisTasigna | $91,094 | $191,13213 claims |
| Beigene USA, Inc.Brukinsa | $24 | $145,98412 claims |
| Johnson & JohnsonXarelto | $28 | $40,24150 claims |
| AbbVieCreon | $21 | $31,66721 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 370 hematology & oncology providers in Georgia.
Other hematology & oncology in Marietta
- Steven McCuneMarietta$19.5M
- Raul OyolaMarietta$2.1M
- Louis GarrotMarietta$1.3M
- Dean KirkelMarietta$898K
- Zulfiqar MalikMarietta$824K
- Mehmet BilenAtlanta$21.7M
- Ajay NookaAtlanta$19.3M
- Olatunji AleseAtlanta$15.5M
- Jonathon CohenAtlanta$8.7M
- Ticiana LealAtlanta$6.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.